// App-Quantinova.ai

2131 : Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

Researchers

Presenter

  • Alen Zabotti

Principal Investigators

  • Sarah Ohrndorf

  • William Tillett

  • Marlies Neuhold

  • Michel van Speybroeck

  • Elke Theander

  • Christine Contré

  • Mohamed Sharaf

  • May Shawi

  • Michelle Perate

  • Alexa Kollmeier

  • Pascal Richette

Medical Centers

  • Department of Medical and Biological Sciences, Clinic of Rheumatology, Udine University, Udine, Italy

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen Cilag, Lund, Sweden

  • Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France

  • Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Research & Development, San Diego, CA

  • Federation de Rhumatologie, Hopital Lariboisiere, Assistance Publique-Hopitaux de Paris, Paris, France

Locations

  • Italy

  • Germany

  • United Kingdom

  • Switzerland

  • Belgium

  • Sweden

  • France

  • United Arab Emirates

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved